These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 23278364)

  • 1. Effects of fasting blood glucose, diabetes treatment, blood pressure and anti-hypertension treatment on cardiovascular disease incidence: a 30-year follow-up study of 740 incident patients with Type 2 diabetes.
    Jansson SP; Andersson DK; Svärdsudd K
    Diabet Med; 2013 Mar; 30(3):349-57. PubMed ID: 23278364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of fasting blood glucose levels and blood pressure and treatment of diabetes and hypertension on the incidence of cardiovascular disease: a study of 740 patients with incident Type 2 diabetes with up to 30 years' follow-up.
    Jansson SP; Svärdsudd K; Andersson DK
    Diabet Med; 2014 Sep; 31(9):1055-63. PubMed ID: 24894815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diabetes in treated hypertension is common and carries a high cardiovascular risk: results from a 28-year follow-up.
    Almgren T; Wilhelmsen L; Samuelsson O; Himmelmann A; Rosengren A; Andersson OK
    J Hypertens; 2007 Jun; 25(6):1311-7. PubMed ID: 17563546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic implications of hypoglycaemic episodes during hospitalisation for myocardial infarction in patients with type 2 diabetes: a report from the DIGAMI 2 trial.
    Mellbin LG; Malmberg K; Waldenström A; Wedel H; Rydén L;
    Heart; 2009 May; 95(9):721-7. PubMed ID: 19029171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of antecedent hypertension and follow-up blood pressure on outcomes after high-risk myocardial infarction.
    Thune JJ; Signorovitch J; Kober L; Velazquez EJ; McMurray JJ; Califf RM; Maggioni AP; Rouleau JL; Howlett J; Zelenkofske S; Pfeffer MA; Solomon SD
    Hypertension; 2008 Jan; 51(1):48-54. PubMed ID: 18025296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intensified insulin-based glycaemic control after myocardial infarction: mortality during 20 year follow-up of the randomised Diabetes Mellitus Insulin Glucose Infusion in Acute Myocardial Infarction (DIGAMI 1) trial.
    Ritsinger V; Malmberg K; Mårtensson A; Rydén L; Wedel H; Norhammar A
    Lancet Diabetes Endocrinol; 2014 Aug; 2(8):627-33. PubMed ID: 24831989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial.
    Mellbin LG; Malmberg K; Norhammar A; Wedel H; Rydén L;
    Eur Heart J; 2008 Jan; 29(2):166-76. PubMed ID: 18156614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity.
    Malmberg K; Rydén L; Wedel H; Birkeland K; Bootsma A; Dickstein K; Efendic S; Fisher M; Hamsten A; Herlitz J; Hildebrandt P; MacLeod K; Laakso M; Torp-Pedersen C; Waldenström A;
    Eur Heart J; 2005 Apr; 26(7):650-61. PubMed ID: 15728645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The relationship between glycaemic variability and cardiovascular complications in patients with acute myocardial infarction and type 2 diabetes: a report from the DIGAMI 2 trial.
    Mellbin LG; Malmberg K; Rydén L; Wedel H; Vestberg D; Lind M
    Eur Heart J; 2013 Feb; 34(5):374-9. PubMed ID: 23144046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.
    Chiasson JL; Josse RG; Gomis R; Hanefeld M; Karasik A; Laakso M;
    JAMA; 2003 Jul; 290(4):486-94. PubMed ID: 12876091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of valsartan versus amlodipine in diabetic hypertensive patients with or without previous cardiovascular disease.
    Yamashita K; Kondo T; Muramatsu T; Matsushita K; Nagahiro T; Maeda K; Shintani S; Murohara T
    Am J Cardiol; 2013 Dec; 112(11):1750-6. PubMed ID: 24035165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of gender on prognosis in patients with myocardial infarction and type 2 diabetes.
    Venskutonyte L; Malmberg K; Norhammar A; Wedel H; Rydén L
    J Intern Med; 2010 Jul; 268(1):75-82. PubMed ID: 20210844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism.
    Pessina AC; Ciccariello L; Perrone F; Stoico V; Gussoni G; Scotti A; Muggeo M
    Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):137-47. PubMed ID: 16487914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular outcome of patients with abnormal coronary vasomotion and normal coronary arteriography is worse in type 2 diabetes mellitus than in arterial hypertension: a 10 year follow-up study.
    Nitenberg A; Pham I; Antony I; Valensi P; Attali JR; Chemla D
    Atherosclerosis; 2005 Nov; 183(1):113-20. PubMed ID: 16216594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of RASGRP1 polymorphism with vascular complications in Chinese diabetic patients with glycemic control and antihypertensive treatment.
    Zhou J; Xu B; He F; Shu Y; Chen X; Liu Z; Sun B; Zhang W
    Cardiovasc Diabetol; 2024 May; 23(1):166. PubMed ID: 38730425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationships between the risk of cardiovascular disease in type 2 diabetes patients and both visit-to-visit variability and time-to-effect differences in blood pressure.
    Takao T; Kimura K; Suka M; Yanagisawa H; Kikuchi M; Kawazu S; Matsuyama Y
    J Diabetes Complications; 2015 Jul; 29(5):699-706. PubMed ID: 25861721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Glycemic regulation and management of essential hypertension in diabetics with type 2 diabetes mellitus; the 'United Kingdom prospective diabetes study' of diabetic complications].
    Wolffenbuttel BH; Heine RJ
    Ned Tijdschr Geneeskd; 1999 Jun; 143(23):1197-201. PubMed ID: 10389533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Barzilay JI; Davis BR; Cutler JA; Pressel SL; Whelton PK; Basile J; Margolis KL; Ong ST; Sadler LS; Summerson J;
    Arch Intern Med; 2006 Nov; 166(20):2191-201. PubMed ID: 17101936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relation between cardiovascular complications and blood pressure/blood glucose control in diabetic patients with hypertension receiving long-term candesartan cilexetil therapy: Challenge-DM study.
    Kawamori R; Fujita T; Matsuoka H; Umemura S; Saito Y
    Diabetes Res Clin Pract; 2009 Feb; 83(2):241-8. PubMed ID: 19097664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of Type 2 diabetes and microalbuminuria on future cardiovascular events in patients with clinically manifest vascular disease from the Second Manifestations of ARTerial disease (SMART) study.
    Soedamah-Muthu SS; Visseren FL; Algra A; van der Graaf Y;
    Diabet Med; 2008 Jan; 25(1):51-7. PubMed ID: 18199132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.